Objective   To investigate the efficacy and safety of alfuzosin

an alpha-1 adrenoceptor antagonist

on the treatment of neurogenic voiding dysfunction.    Methods   Totally 109 patients with neurogenic bladder were treated by administration of alfuzosin

a delayed release type 10 mg per night for 12 weeks. Of them

44 were combined with striated muscle relaxants such as baclofen or diazepam. The efficacy were analyzed by comparing the maximal urethral pressure (MUP)

mean residual urine volume (MRUV)

and mean bladder neck openness

(MBNO) before and after the drug usage.    Results   Eight patients (7%) discontinued the trial because of dizziness and postural hypotension

and the other 101 patients completed the trial. MUP was decreased from (69.20±22.97) cmH

2

O to (57.18±19.41) cmH

2

O

MRUV from (120±30) ml to (96±25.5) ml

and MBNO increased from (6±5) mm to (7.67±4.89) mm. Statistical difference was significant (P0.01). But there was no statistical difference between the alfuzosin group and the combination group (P0.05).    Conclusion   Alfuzosin reduces the urethral pressure and residual urine volume of neurogenic bladder

and improves the voiding conditions.